S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Forecast, Price & News

$0.18
0.00 (0.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.17
$0.18
50-Day Range
$0.13
$0.21
52-Week Range
$0.12
$1.45
Volume
137,957 shs
Average Volume
436,879 shs
Market Capitalization
$6.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

NeuBase Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
6,076.3% Upside
$11.00 Price Target
Short Interest
Healthy
2.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.40) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars


NBSE stock logo

About NeuBase Therapeutics (NASDAQ:NBSE) Stock

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm's therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBSE Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
NeuBase Therapeutics to lose president
NeuBase Therapeutics begins strategic restructuring
See More Headlines
Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBSE Company Calendar

Last Earnings
5/11/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBSE
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+4,672.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
3 Analysts

Profitability

Net Income
$-33,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.43 per share

Miscellaneous

Free Float
27,826,000
Market Cap
$6.02 million
Optionable
Not Optionable
Beta
1.01

Key Executives

  • Dietrich A. StephanDietrich A. Stephan
    Chief Executive Officer & Director
  • Todd P. Branning
    Chief Financial Officer
  • Curt W. Bradshaw
    Chief Scientific Officer
  • Anthony Rossomando
    Chief Technology Officer
  • Ron Sarkar
    Vice President-Business Development













NBSE Stock - Frequently Asked Questions

Should I buy or sell NeuBase Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NBSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBSE, but not buy additional shares or sell existing shares.
View NBSE analyst ratings
or view top-rated stocks.

What is NeuBase Therapeutics' stock price forecast for 2023?

3 analysts have issued 12 month target prices for NeuBase Therapeutics' stock. Their NBSE share price forecasts range from $7.00 to $15.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 6,076.3% from the stock's current price.
View analysts price targets for NBSE
or view top-rated stocks among Wall Street analysts.

How have NBSE shares performed in 2023?

NeuBase Therapeutics' stock was trading at $0.1902 at the beginning of the year. Since then, NBSE shares have decreased by 6.4% and is now trading at $0.1781.
View the best growth stocks for 2023 here
.

When is NeuBase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our NBSE earnings forecast
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02.

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).

What is NeuBase Therapeutics' stock symbol?

NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."

Who are NeuBase Therapeutics' major shareholders?

NeuBase Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.52%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Dietrich A Stephan, Eric I Richman, Todd P Branning and William Roland Mann.
View institutional ownership trends
.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuBase Therapeutics' stock price today?

One share of NBSE stock can currently be purchased for approximately $0.18.

How much money does NeuBase Therapeutics make?

NeuBase Therapeutics (NASDAQ:NBSE) has a market capitalization of $6.02 million. The company earns $-33,780,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How can I contact NeuBase Therapeutics?

NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The official website for the company is www.neubasetherapeutics.com. The company can be reached via phone at (164) 645-1790 or via email at daniel@lifesciadvisors.com.

This page (NASDAQ:NBSE) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -